Free Trial

Corcept Therapeutics (CORT) Competitors

Corcept Therapeutics logo
$69.58 -0.15 (-0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$69.74 +0.17 (+0.24%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CORT vs. ANVS, RPRX, JAZZ, PRGO, SUPN, PCRX, NKTR, OMER, ASMB, and CPIX

Should you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Annovis Bio (ANVS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "medical" sector.

Corcept Therapeutics vs. Its Competitors

Corcept Therapeutics (NASDAQ:CORT) and Annovis Bio (NYSE:ANVS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 20.8% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Corcept Therapeutics had 10 more articles in the media than Annovis Bio. MarketBeat recorded 11 mentions for Corcept Therapeutics and 1 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 1.39 beat Annovis Bio's score of 0.00 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corcept Therapeutics
7 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Annovis Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Corcept Therapeutics presently has a consensus price target of $134.50, indicating a potential upside of 93.30%. Annovis Bio has a consensus price target of $18.00, indicating a potential upside of 672.53%. Given Annovis Bio's higher possible upside, analysts clearly believe Annovis Bio is more favorable than Corcept Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Annovis Bio
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60

Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$675.04M10.86$141.21M$1.1361.58
Annovis BioN/AN/A-$24.59M-$2.04-1.14

Corcept Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.

Corcept Therapeutics has a net margin of 18.51% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 20.10% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Corcept Therapeutics18.51% 20.10% 16.20%
Annovis Bio N/A -206.01%-158.26%

Summary

Corcept Therapeutics beats Annovis Bio on 12 of the 14 factors compared between the two stocks.

Get Corcept Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CORT vs. The Competition

MetricCorcept TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.35B$2.51B$5.78B$9.80B
Dividend YieldN/A1.68%3.95%4.02%
P/E Ratio61.5822.8231.2626.59
Price / Sales10.86733.77465.87173.66
Price / Cash56.14177.0937.7359.36
Price / Book11.546.1810.046.68
Net Income$141.21M$32.94M$3.27B$265.59M
7 Day Performance-1.97%0.99%3.17%3.42%
1 Month Performance0.62%1.69%4.34%1.09%
1 Year Performance102.03%11.44%44.12%23.84%

Corcept Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CORT
Corcept Therapeutics
4.7604 of 5 stars
$69.58
-0.2%
$134.50
+93.3%
+101.2%$7.35B$675.04M61.58300Positive News
ANVS
Annovis Bio
1.9792 of 5 stars
$2.24
-5.5%
$18.00
+703.6%
-74.0%$43.66MN/A-1.103
RPRX
Royalty Pharma
4.9815 of 5 stars
$35.99
-0.9%
$48.00
+33.4%
+26.4%$21.18B$2.31B20.8080Positive News
JAZZ
Jazz Pharmaceuticals
4.7536 of 5 stars
$124.59
+1.2%
$181.43
+45.6%
+8.4%$7.56B$4.07B-18.512,800Positive News
Analyst Forecast
PRGO
Perrigo
4.9785 of 5 stars
$23.82
-2.8%
$33.00
+38.6%
-18.3%$3.28B$4.37B-41.068,379Positive News
SUPN
Supernus Pharmaceuticals
2.0975 of 5 stars
$44.43
-1.0%
$41.00
-7.7%
+29.1%$2.49B$665.13M38.63580Positive News
Insider Trade
PCRX
Pacira BioSciences
3.337 of 5 stars
$25.36
-1.9%
$30.83
+21.6%
+80.5%$1.14B$705.85M-9.12720News Coverage
Positive News
NKTR
Nektar Therapeutics
4.2785 of 5 stars
$27.14
+0.4%
$88.33
+225.5%
+56.2%$516.20M$98.43M-3.09220
OMER
Omeros
4.1017 of 5 stars
$4.35
-1.1%
$18.00
+313.8%
+3.4%$296.06MN/A-2.06210Positive News
ASMB
Assembly Biosciences
4.0659 of 5 stars
$26.62
-1.2%
$38.67
+45.3%
+57.5%$204.18M$28.52M-4.77100
CPIX
Cumberland Pharmaceuticals
0.6023 of 5 stars
$3.26
-0.9%
N/A+144.6%$48.77M$37.87M-14.8280Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:CORT) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners